Cell & Gene Therapy
Cell & Gene Therapy
Marken has a unique cell and gene therapy offering, supporting both clinical and commercial therapies with multi-dimensional logistics and global cryogenic network to deliver tomorrow’s advanced therapy lifelines.
Go beyond with us
Our ever-evolving portfolio includes secure, closed loop supply chain services, end-to-end visibility through data-driven tracking solutions and 24/7 cell and gene control tower monitoring oversight. As the leading partner to safeguard these ultra-sensitive, time and temperature-critical treatments, we go beyond cell and gene orchestration to support patients who rely on us to anticipate, innovate and deliver.
Related resources
Orchestrating Outcomes for Logistics – Driving Digitalization and Patient-Centric Innovation in Pharma Supply Chains – Part 2
20 September 2024
Part 2 of our Orchestrating Outcomes for Logistics interview series highlights how building resilience into every link of the supply chain drives precision, progress and patient-centric innovation
Orchestrating Outcomes for Logistics – Driving Digitalization and Patient-Centric Innovation in Pharma Supply Chains – Part 1
20 September 2024
To drive supply chain digitalization, it’s essential to leverage data not only to address immediate challenges but to anticipate and prevent disruptions
Marken Delivers Life-Saving Gene Therapy Treatment Over 3,000 Miles From Germany to the UAE in Under 48 Hours
18 September 2024
Marken was tasked with delivering a life-saving gene therapy treatment for a child suffering from Duchenne muscular dystrophy (DMD) in…
Marken seamlessly orchestrates distribution of first commercial CAR-T therapy drug product from USA to Japan
17 October 2023
Marken successfully orchestrated the distribution of the first commercial CAR-T therapy drug product from the USA to a hospital in…
Marken’s 24/7 Cell & Gene Control Tower Provides Agile Solution for Critical Shipments
9 February 2023
Marken’s Cell and Gene Control Tower re-routed six critical shipments of CAR-T drug products from Amsterdam to the UK and…
Operational Excellence Overcomes Obstacles to Deliver Critical Autologous Cell Therapy
9 February 2023
Marken utilized operational excellence to deliver a critical autologous cell therapy. Although there were many challenges, Marken was able to…
Marken Successfully Safeguards the Viability of Pharmaceutical Samples Within 42 Hours
4 January 2023
The distribution of critical cell samples requires an agile strategy with contingency planning and regulatory expertise to ensure seamless delivery…
Happy Holidays from Marken
21 December 2022
At Marken, we are passionate about patients – always finding a way to deliver for our clients – on-time, within…
Marken Overcomes Multiple Obstacles To Successfully Deliver Critical Stem Cell Samples Across The Globe
9 December 2022
Stem cell samples require extremely tight 24-hour turnaround times in order to be modified and processed for critical cell therapy…
The Complex Demands of Personalized Medicine Supply Chains.
26 July 2021
Outsourcing-Pharma and Nina Vas, Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, discuss the specific requirements involved…
Evaluating a Clinical Supply Chain Partner to Meet Your Vaccine Trial Needs.
23 April 2021
It is essential for pharmaceutical companies to evaluate many factors when choosing a clinical supply chain partner. With today’s global…
Decentralized Trials Call for Supply Chain Flexibility: Marken
8 April 2021
Outsourcing-Pharma and Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, Nina Vas, and Senior Director of Global…
Delivering What Matters
Understanding why we must adapt, continuously asking ourselves how we can change what matters is how we keep on delivering it.
Login and quick links